Buy vs Build – HCP Engagement Management

It is imperative that life sciences companies implement a sound approach to compliantly plan, engage and pay HCPs that meet company objectives while meeting all company policies and procedures and compliance regulations via an efficient and effective process driven by technology. Understanding how to achieve that goal requires 5 steps: evaluate, identify, specify, assess and […]

Buy vs Build – HCP Engagement Management2024-06-27T22:09:17+00:00

Bridging the HCP Engagement Gap Between Compliance and Commercial

Life sciences companies often struggle to balance the needs and wants of internal stakeholders when it comes to managing paid HCP/O engagements: compliance wants to mitigate risk, commercial wants to grow the business and manage relationships and IT wants an integrated solution to ensure all stakeholders are happy in achieving their objectives.

MediSpend’s Engagement Manager is […]

Bridging the HCP Engagement Gap Between Compliance and Commercial2024-06-27T22:25:39+00:00

Evolving Compliance: How to Remain Nimble While Mitigating Risk

The life sciences industry has seen settlement after settlement which has led to an increased focus on developing and evolving compliance programs. As an organization grows, it is important that compliance programs evolve. Having an appropriate governance framework in place and using technology to streamline your processes allows companies to be nimble while mitigating risk.

Listen […]

Evolving Compliance: How to Remain Nimble While Mitigating Risk2024-06-27T22:26:24+00:00

Analysis of 2020 CMS Open Payments Data and Future Trends

As evidenced by the published CMS Open Payments data, it is clear that 2020 brought a multitude of challenges and new business processes for life science organizations. Understanding how spend changed in 2020 is important; it provides a window into how policies may have changed and how they will continue to evolve with the new […]

Analysis of 2020 CMS Open Payments Data and Future Trends2024-06-27T22:31:02+00:00

Analysis of OIG Special Fraud Alert on Speaker Programs & Assessment of Future Activities

Speaker programs are an important aspect of healthcare professional training and education; however, they also pose significant risk to your organization if not managed properly. In November 2020, a special fraud alert was issued by the Office of the Inspector General (OIG) highlighting the potential fraud and abuse related to the offer or payment of […]

Analysis of OIG Special Fraud Alert on Speaker Programs & Assessment of Future Activities2024-06-27T22:50:15+00:00

Navigating New Compliance Regulations in the Life Sciences Industry

Life sciences companies face a multitude of changing global transparency reporting regulations, including the expansion of CMS’ Open Payments program which includes a wide range of new covered recipients, as well as updates to European guidelines around payment disclosures. Is your organization ready to adapt and navigate the new requirements successfully?

Listen as MediSpend’s Chief Commercial […]

Navigating New Compliance Regulations in the Life Sciences Industry2024-06-27T22:36:32+00:00

What Does the CCPA Mean for Life Sciences Companies?

With the California Consumer Privacy Act (CCPA) enforcement going into effect this year, organizations want to know how the law will affect their processes and what it takes to be compliant.

Listen as MediSpend’s Chief Legal and Privacy Officer, Tim Robinson, and MediSpend’s VP of Compliance Solutions, Diana Borges, discuss the impact the CCPA will have […]

What Does the CCPA Mean for Life Sciences Companies?2024-06-27T22:39:25+00:00

Overview of the DOJ’s 2019 Evaluation of Corporate Compliance Programs Guidance

Regardless of the size of your organization or how mature your compliance program is, we all face the same challenge — the ability to identify and mitigate risk. As businesses get more complex, enforcement risks continue to increase. Does your compliance program have the ability to proactively identify and manage those risks?

Listen as MediSpend’s VP […]

Overview of the DOJ’s 2019 Evaluation of Corporate Compliance Programs Guidance2024-06-27T22:40:07+00:00
Go to Top